These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 23663105)

  • 21. The effects of sample handling and N-phenylmaleimide on concentration of adrenocorticotrophic hormone in equine plasma.
    Rendle DI; Litchfield E; Gough S; Cowling A; Hughes KJ
    Equine Vet J; 2015 Sep; 47(5):587-91. PubMed ID: 24980684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytokine dysregulation in aged horses and horses with pituitary pars intermedia dysfunction.
    McFarlane D; Holbrook TC
    J Vet Intern Med; 2008; 22(2):436-42. PubMed ID: 18371032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma concentrations of inflammatory markers in previously laminitic ponies.
    Wray H; Elliott J; Bailey SR; Harris PA; Menzies-Gow NJ
    Equine Vet J; 2013 Sep; 45(5):546-51. PubMed ID: 23418944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computed tomographic findings in the pituitary gland and brain of horses with pituitary pars intermedia dysfunction.
    Pease AP; Schott HC; Howey EB; Patterson JS
    J Vet Intern Med; 2011; 25(5):1144-51. PubMed ID: 21985144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic frequency, response to therapy, and long-term prognosis among horses and ponies with pituitary par intermedia dysfunction, 1993-2004.
    Rohrbach BW; Stafford JR; Clermont RS; Reed SM; Schott HC; Andrews FM
    J Vet Intern Med; 2012; 26(4):1027-34. PubMed ID: 22524260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of combined testing to simultaneously diagnose pituitary pars intermedia dysfunction and insulin dysregulation in horses.
    Horn R; Bertin FR
    J Vet Intern Med; 2019 Sep; 33(5):2249-2256. PubMed ID: 31498947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses.
    McFarlane D; Cribb AE
    Am J Vet Res; 2005 Dec; 66(12):2065-72. PubMed ID: 16379648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement of cortisol concentration in the tears of horses and ponies with pituitary pars intermedia dysfunction.
    Hart KA; Kitchings KM; Kimura S; Norton NA; Myrna KE
    Am J Vet Res; 2016 Nov; 77(11):1236-1244. PubMed ID: 27805438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationships of inflamm-aging with circulating nutrient levels, body composition, age, and pituitary pars intermedia dysfunction in a senior horse population.
    Siard-Altman MH; Harris PA; Moffett-Krotky AD; Ireland JL; Betancourt A; Barker VD; McMurry KE; Reedy SE; Adams AA
    Vet Immunol Immunopathol; 2020 Mar; 221():110013. PubMed ID: 32058159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole-body phenylalanine kinetics and skeletal muscle protein signaling in horses with pituitary pars intermedia dysfunction.
    Mastro LM; Adams AA; Urschel KL
    Am J Vet Res; 2014 Jul; 75(7):658-67. PubMed ID: 24959733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigation of single and paired measurements of adrenocorticotropic hormone for the diagnosis of pituitary pars intermedia dysfunction in horses.
    Rendle DI; Duz M; Beech J; Parkin T; Durham AE
    J Vet Intern Med; 2015 Jan; 29(1):355-61. PubMed ID: 25312676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does oral prednisolone treatment increase the incidence of acute laminitis?
    Jordan VJ; Ireland JL; Rendle DI
    Equine Vet J; 2017 Jan; 49(1):19-25. PubMed ID: 26713748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of advanced age and pituitary pars intermedia dysfunction on components of the acute phase reaction in horses.
    Zak A; Siwinska N; Elzinga S; Barker VD; Stefaniak T; Schanbacher BJ; Place NJ; Niedzwiedz A; Adams AA
    Domest Anim Endocrinol; 2020 Jul; 72():106476. PubMed ID: 32380311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.
    Fortin JS; Benskey MJ; Lookingland KJ; Patterson JS; Howey EB; Goudreau JL; Schott HC
    BMC Vet Res; 2020 Sep; 16(1):356. PubMed ID: 32977825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case series of equine pituitary pars intermedia dysfunction in a tropical climate.
    Spelta CW; Axon JE
    Aust Vet J; 2012 Nov; 90(11):451-6. PubMed ID: 23106327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
    Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA
    Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phenotypic, hormonal, and clinical characteristics of equine endocrinopathic laminitis.
    de Laat MA; Sillence MN; Reiche DB
    J Vet Intern Med; 2019 May; 33(3):1456-1463. PubMed ID: 30697823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacologic basis for the treatment of endocrinopathic laminitis.
    Durham A
    Vet Clin North Am Equine Pract; 2010 Aug; 26(2):303-14. PubMed ID: 20699177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. α-Melanocyte--stimulating hormone and adrenocorticotropin concentrations in response to thyrotropin-releasing hormone and comparison with adrenocorticotropin concentration after domperidone administration in healthy horses and horses with pituitary pars intermedia dysfunction.
    Beech J; McFarlane D; Lindborg S; Sojka JE; Boston RC
    J Am Vet Med Assoc; 2011 May; 238(10):1305-15. PubMed ID: 21568777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endocrinopathic Laminitis.
    Grenager NS
    Vet Clin North Am Equine Pract; 2021 Dec; 37(3):619-638. PubMed ID: 34674908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.